12. Teleflex (NYSE:TFX): +54.4%
Teleflex is involved in a wide breadth of medical device product areas, including vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. The Wayne, Pa.–based company has enjoyed strong growth. In November, the company announced that its third-quarter profits were up 16.1% year-over-year, to $77 million, with sales growth of 17.4%, to $534.7 million. Both sales and profits topped Wall Street expectations.
“In addition, despite having to deal with certain weather-related delays during the third quarter, Teleflex saw an acceleration in its organic revenue growth rate from the levels achieved earlier this year, thanks in part to progress made in our distributor-to-direct conversion in Asia,” CEO Benson Smith said last month.
“Finally, on the first day of the fourth quarter we completed the acquisition of NeoTract. This acquisition, coupled with revenue- and non-revenue-dependent opportunities within our base business, positions Teleflex to succeed for several years in the future.”